Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05409118
Other study ID # CP-0022
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 2024
Est. completion date December 2030

Study information

Verified date February 2024
Source Endologix
Contact Noel DeSisto
Phone 864-270-8524
Email ndesisto@endologix.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 450
Est. completion date December 2030
Est. primary completion date December 2030
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Adult age 21 and older - Subjects with minimum of 2 year life expectancy - Subjects have signed the informed consent document - Subjects with unruptured infrarenal AAA who are assessed by the Investigator to be eligible for endovascular Abdominal Aortic Aneurysm Repair with the trial devices. - Patient must be able and willing to comply with all required follow-up exams. Exclusion Criteria: - Currently participating in another trial where the primary endpoint has not been reached yet. - Known allergy to any of the device components - Pregnant (females of childbearing potential only) - Known connective tissue disorders - Known active infection - Subjects with pre-existing EVAR, i.e., in need of repair/intervention of a previously failed EVAR. - Patient has other medical, social, or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.

Study Design


Intervention

Device:
Alto Abdominal Stent Graft System
Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
FDA Approved EVAR AAA Graft Systems
FDA approved comparator of choice

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Endologix

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Freedom from Aneurysm-Related Complications (ARC) Composite endpoint consisting of aneurysm-related death, aneurysm rupture, conversion to open surgery, type I and III endoleaks, device migration (>10mm), aneurysm sac enlargement (>5mm), occlusion, and freedom from device-related interventions Through 5 Years
Primary Neck Dilation in mm Through 5 Years
Secondary Number of Major Adverse Events (MAEs) All-cause mortality, Bowel ischemia, Myocardial infarction, Paraplegia, Renal Failure, Respiratory Failure, Stroke, Index Procedural Blood Loss = 1000mL [Time Frame: At 30 days and 12 months]
Secondary Count of participants All Cause Mortality At 30 days, 12 months, and annually up to five years
Secondary Count of participants AAA-related Mortality At 30 days, 12 months, and annually up to five years
Secondary Number of Type Ia endoleaks At 30 days, 12 months, and annually up to five years
Secondary Number of Type Ib At 30 days, 12 months, and annually up to five years
Secondary Number of Type II At 30 days, 12 months, and annually up to five years
Secondary Number of Type III At 30 days, 12 months, and annually up to five years
Secondary Number of Type IV At 30 days, 12 months, and annually up to five years
Secondary Number of Unknown Enooleaks At 30 days, 12 months, and annually up to five years
Secondary Number of Secondary interventions At 30 days, 12 months, and annually up to five years
Secondary Count of subjects lacking device integrity device patency (stenosis and occlusion) and integrity (kinking, fracture, and polymer leak) At 30 days, 12 months, and annually up to five years
Secondary Count of aneurysm ruptures At 30 days, 12 months, and annually up to five years
Secondary Count of participants with conversion to open surgery At 30 days, 12 months, and annually up to five years
Secondary Count of participants with type I and III endoleaks At 30 days, 12 months, and annually up to five years
Secondary Count of participants with device migration (>10mm) 12 months, and annually up to five years
Secondary Count of participants with aneurysm sac enlargement (>5mm) 12 months, and annually up to five years
Secondary Count of subjects with occlusion 30 days, 12 months, and annually up to five years]
Secondary Number of Participants with Freedom From device-related interventions 30 days, 12 months, and annually up to five years]
See also
  Status Clinical Trial Phase
Recruiting NCT05064540 - JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization N/A
Completed NCT03762525 - Iliac Branch Device Movement During Cardiac Cycle (IBD-dynamics) N/A
Not yet recruiting NCT02843854 - Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms Phase 1
Completed NCT04080557 - Abdominal Aortic Aneurysm Patients Remain at Risk for Delirium on the Surgical Ward After Intensive Care Unit Dismissal
Recruiting NCT02179801 - Screening Cardiovascular Patients for Aortic aNeurysms (SCAN) N/A
Recruiting NCT05376514 - Central Blood Pressure and Variability Evaluation
Active, not recruiting NCT05133492 - First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA) N/A
Terminated NCT02485496 - E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms
Terminated NCT02461524 - Endurant Evo International Clinical Trial N/A
Not yet recruiting NCT03407664 - NHS AAA Screening Programme Data Linkage With HES and ONS Datasets
Active, not recruiting NCT02692664 - Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft
Terminated NCT02393716 - Endurant Evo US Clinical Trial N/A